BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 38671465)

  • 1. Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease.
    Mahboobipour AA; Ala M; Safdari Lord J; Yaghoobi A
    Orphanet J Rare Dis; 2024 Apr; 19(1):175. PubMed ID: 38671465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
    Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
    JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
    Porath B; Gainullin VG; Cornec-Le Gall E; Dillinger EK; Heyer CM; Hopp K; Edwards ME; Madsen CD; Mauritz SR; Banks CJ; Baheti S; Reddy B; Herrero JI; Bañales JM; Hogan MC; Tasic V; Watnick TJ; Chapman AB; Vigneau C; Lavainne F; Audrézet MP; Ferec C; Le Meur Y; Torres VE; ; ; Harris PC
    Am J Hum Genet; 2016 Jun; 98(6):1193-1207. PubMed ID: 27259053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics and mechanisms of hepatic cystogenesis.
    van de Laarschot LFM; Drenth JPH
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1491-1497. PubMed ID: 28782656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
    Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
    JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Spectrum of Polycystic Kidney and Liver Diseases and the Resulting Phenotypes.
    Yang H; Sieben CJ; Schauer RS; Harris PC
    Adv Kidney Dis Health; 2023 Sep; 30(5):397-406. PubMed ID: 38097330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilia and polycystic kidney disease.
    Ma M
    Semin Cell Dev Biol; 2021 Feb; 110():139-148. PubMed ID: 32475690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver cyst gene knockout in cholangiocytes inhibits cilium formation and Wnt signaling.
    Wills ES; Te Morsche RHM; van Reeuwijk J; Horn N; Geomini I; van de Laarschot LFM; Mans DA; Ueffing M; Boldt K; Drenth JPH; Roepman R
    Hum Mol Genet; 2017 Nov; 26(21):4190-4202. PubMed ID: 28973524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.
    Lanktree MB; Haghighi A; Guiard E; Iliuta IA; Song X; Harris PC; Paterson AD; Pei Y
    J Am Soc Nephrol; 2018 Oct; 29(10):2593-2600. PubMed ID: 30135240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
    Cnossen WR; Drenth JP
    Orphanet J Rare Dis; 2014 May; 9():69. PubMed ID: 24886261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.
    Cornec-Le Gall E; Torres VE; Harris PC
    J Am Soc Nephrol; 2018 Jan; 29(1):13-23. PubMed ID: 29038287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the variability of the ADPKD-GANAB clinical phenotype in a family of Italian ancestry.
    Delbarba E; Econimo L; Dordoni C; Martin E; Mazza C; Savoldi G; Alberici F; Scolari F; Izzi C
    J Nephrol; 2022 Mar; 35(2):645-652. PubMed ID: 34357571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Analysis of Severe Polycystic Liver Disease in Japan.
    Mizuno H; Besse W; Sekine A; Long KT; Kurihara S; Oba Y; Yamanouchi M; Hasegawa E; Suwabe T; Sawa N; Ubara Y; Somlo S; Hoshino J
    Kidney360; 2024 May; ():. PubMed ID: 38689396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic Liver Disease: Advances in Understanding and Treatment.
    Masyuk TV; Masyuk AI; LaRusso NF
    Annu Rev Pathol; 2022 Jan; 17():251-269. PubMed ID: 34724412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Targets in Polycystic Liver Disease.
    Masyuk TV; Masyuk AI; LaRusso NF
    Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of polycystic liver diseases.
    Lee-Law PY; van de Laarschot LFM; Banales JM; Drenth JPH
    Curr Opin Gastroenterol; 2019 Mar; 35(2):65-72. PubMed ID: 30652979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterozygosity of ALG9 in Association with Autosomal Dominant Polycystic Liver Disease.
    Boerrigter MM; Duijzer R; Te Morsche RHM; Drenth JPH
    Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761895
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Besse W; Chang AR; Luo JZ; Triffo WJ; Moore BS; Gulati A; Hartzel DN; Mane S; ; Torres VE; Somlo S; Mirshahi T
    J Am Soc Nephrol; 2019 Nov; 30(11):2091-2102. PubMed ID: 31395617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
    Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
    Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.